Get the Stockscreener App
38.54
0.73%
0.28
After Hours:
38.54
Harrow Inc stock is traded at $38.54, with a volume of 229.01K.
It is up +0.73% in the last 24 hours and down -3.24% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$38.26
Open:
$37.96
24h Volume:
229.01K
Relative Volume:
0.36
Market Cap:
$1.44B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-235.72
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
+3.41%
1M Performance:
-3.24%
6M Performance:
-1.73%
1Y Performance:
+6.46%
1-Day Range:
$37.73
$38.66
1-Week Range:
$36.25
$39.33
52-Week Range:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
38.54 | 1.58B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Inc stock gains as analysts see strong revenue growth ahead - AD HOC NEWS
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow to Participate in Three Investor Conferences in September - Yahoo Finance
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - MarketBeat
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Harrow announces product updates - Nashville Post
Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance
Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus
A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus
HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus
HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Harrow Q2 2026 slides: strong demand growth amid profitability push By Investing.com - Investing.com Canada
Harrow Releases Q2 2026 Financial Results - AlphaStreet
Harrow Q2 Earnings Call Highlights - MarketBeat
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
Harrow Health, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):